HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

Results suggest new hope for patients with refractory chronic lymphocytic leukemia Data to support BLA submission

BARCELONA, SPAIN, June 12 ---ILEXTM Oncology, Inc. (NASDAQ: ILXO) and LeukoSite, Inc. (NASDAQ: LKST) today announced final results from an international, multi-center, pivotal Phase II clinical trial of CAMPATHR for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who are refractory to fludarabine. Results of the trial were presented this weekend at the 4th Congress of the European Haematology Association (EHA) by Michael J. Keating, MB, BS, of the M.D. Anderson Cancer Center, one of the trial's principal investigators and an internationally recognized expert in CLL. The companies plan to submit a Biologics License Application (BLA) based largely on these results later this year.

"The results of this trial are encouraging," said Dr. Keating, Associate Head for Clinical Research and Professor of Medicine and internist for the Department of Leukemia at M.D. Anderson Cancer Center. "The data suggest that CAMPATH may provide an important new treatment option for fludarabine-refractory patients, a group for whom the prognosis has, to date, been extremely poor. While the treatment of patients with leukemia has relied on chemotherapeutic agents, the use of monoclonal antibodies is an innovative approach to circumventing the disease's mechanisms for resistance."

The non-comparative trial, involved 93 previously treated patients who had received prior alkylating agents and failed fludarabine therapy (median of three prior treatment regimens). For these patients, the median life expectancy is usually six to nine months.

In the trial, patients participating at the 20 clinical sites in the United States and Europe received 30 mg of CAMPATH on an outpatient basis, as an intravenous infusion, three times a week, for four to 12 weeks. The dose was gradually escalated over the first week to 30 mg, in or
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/14/2018)... ... August 14, 2018 , ... Eagle Merchant Partners and ... provider of residential and commercial recreational surfacing products across the country. , The ... used across a wide range of markets and customers. Founded in 1998, Recreational ...
(Date:8/11/2018)... ... August 10, 2018 , ... Dr. Siavash Eftekhari, Oral and Maxillofacial Surgeon ... a week-long international outpost trip to deliver dental care in impoverished communities. Along with ... Dr. Eftekhari volunteered his time to help deliver care to over 550 individuals in ...
(Date:8/11/2018)... ST. PETERSBURG, Fla. (PRWEB) , ... August 10, 2018 , ... ... health and wellness of children in the region by utilizing a population health perspective ... of a population by ensuring families are being treated at the right facility or ...
(Date:8/11/2018)... ... August 11, 2018 , ... Financial ... Award in the Executive of the Year-Business category in The 15th Annual International ... program. All individuals and organizations worldwide – public and private, for-profit and non-profit, ...
(Date:8/9/2018)... ... 2018 , ... Lyme disease is one of the fastest growing epidemics to ... – a 25-fold increase since surveillance began in 1982. According to a new report ... states and the District of Columbia. Yet, Lyme and other insect borne illnesses are ...
Breaking Medicine News(10 mins):
(Date:8/2/2018)... ... August 02, 2018 , ... ... gummy smile for custom crown lengthening treatment at his Eden Prairie, ... line and an unsteady self-conscious. Using decades of experience, Dr. Sanchez is excited ...
(Date:8/2/2018)... ... August 02, 2018 , ... Juan M. Montero, ... international leader of sustainable advocacy. Sharon Kleyne, host of the internationally syndicated radio ... & Your Health sponsored by Nature’s Tears® EyeMist® on VoiceAmerica and World Talk ...
(Date:8/2/2018)... ... August 02, 2018 , ... The Team from Hennessey Performance (HPE) has built ... production of a limited production commemorative vehicle: The 2019 Hennessey Heritage Edition Mustang. ... V8 engine produces 808 horsepower at 7,200 rpm and 677 lb-ft of torque at ...
Breaking Medicine Technology:
Cached News: